Axogen Amends 8-K/A on Executive Changes, Compensation

Ticker: AXGN · Form: 8-K/A · Filed: Jan 5, 2024 · CIK: 805928

Axogen, Inc. 8-K/A Filing Summary
FieldDetail
CompanyAxogen, Inc. (AXGN)
Form Type8-K/A
Filed DateJan 5, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $60,437, $25,000
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: amendment, executive-changes, compensation, corporate-governance

TL;DR

**Axogen just amended an 8-K/A about executive changes and pay, signaling a correction to prior info.**

AI Summary

Axogen, Inc. filed an amended 8-K/A on January 5, 2024, to correct a previous filing from December 4, 2023. This amendment specifically addresses Item 5.02, which covers changes in directors or officers and their compensation arrangements. While the filing doesn't detail the specific changes, it indicates that the original report needed clarification regarding these executive and compensation matters. This matters to investors because changes in leadership or executive pay can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.

Why It Matters

This amendment signals that there were inaccuracies or omissions in Axogen's initial report regarding executive leadership and compensation, which are key indicators of corporate governance and stability. Investors should pay attention to the details of these changes as they become available, as they can influence the company's strategic direction and financial health.

Risk Assessment

Risk Level: medium — An amendment to an 8-K, especially concerning executive changes and compensation, can indicate initial reporting errors or ongoing adjustments, which introduces a moderate level of uncertainty for investors.

Analyst Insight

A smart investor would monitor for a subsequent filing or press release from Axogen, Inc. that provides the specific details of the executive and compensation changes that necessitated this amendment, as these details could impact future company performance and valuation.

Key Players & Entities

  • Axogen, Inc. (company) — the registrant filing the 8-K/A
  • December 4, 2023 (date) — date of the earliest event reported in the original 8-K
  • January 5, 2024 (date) — date the 8-K/A was filed
  • 001-36046 (company) — Commission File Number for Axogen, Inc.
  • AXGN (company) — trading symbol for Axogen, Inc. on Nasdaq

FAQ

What is the purpose of this 8-K/A filing by Axogen, Inc.?

This 8-K/A (Amendment No. 1) was filed by Axogen, Inc. to amend a previous Current Report on Form 8-K, specifically regarding Item 5.02, which pertains to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and Item 9.01, 'Financial Statements and Exhibits'.

What was the original date of the event reported in the initial 8-K that this amendment refers to?

The original event reported in the initial 8-K, which this amendment refers to, occurred on December 4, 2023, as stated in the 'Date of Report (Date of earliest event reported)' section.

What is Axogen, Inc.'s trading symbol and on which exchange is it registered?

Axogen, Inc.'s trading symbol is AXGN, and its Common Stock, $0.01 par value, is registered on The Nasdaq Stock Market.

What is the business address of Axogen, Inc.?

The business address of Axogen, Inc. is 13631 Progress Boulevard, Suite 400, Alachua, Florida, 32615.

Which specific items of the 8-K are being amended by this filing?

This 8-K/A specifically amends Item 5.02, titled 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers,' and Item 9.01, titled 'Financial Statements and Exhibits'.

Filing Stats: 750 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-01-05 17:21:43

Key Financial Figures

  • $0.01 — ange on which registered Common Stock, $0.01 par value AXGN The Nasdaq Stock Market
  • $60,437 — will also receive a lump sum payment of $60,437.83, which represents the amount of bonu
  • $25,000 — ole and other matters, and will be paid $25,000 per month for such consulting services.

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. See the Exhibit index below, which is incorporated herein by reference. Exhibit No. Description of Exhibit 10.1 Separation, Waiver and Release of Claims Agreement, dated January 5, 2024, between the Company and Peter Mariani 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AXOGEN, INC. Dated: January 5, 2024 By: /s/ Marc Began Marc Began Executive Vice President, General Counsel, and Chief Compliance Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.